Ilene Weitz
Hematology · Los Angeles, CANPI 1790715399
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 83.2% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $144,432 and has fallen 70.7% since, to $42,349 in 2025. Among hematology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 715 payments — averaging $882.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$525K
- Novartis$25K
- Sanofi$23K
- Alnylam Pharmaceuticals Inc.$17K
- Recordati_rare_diseases_inc.$11K
- Bioverativ Therapeutics Inc.$6K
- plus $23K from 18 others
Across 118 payments — averaging $39,112 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$4.4M
- Bioverativ Therapeutics Inc.$83K
- Sanofi$46K
- Takeda Pharmaceuticals U.S.A., Inc.$40K
- Sanofi US Services Inc.$19K
- UCB SA$3K
- plus $5K from 3 others
What the payments were for
- Consulting fees$153,33024%
- Speaking & faculty fees$376,53560%
- Grants$5,6791%
- Travel & lodging$76,93112%
- Food & beverage$18,0773%
- Education$1380%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 530 | $524,549 |
| Novartis | 42 | $25,412 |
| Sanofi | 35 | $22,971 |
| Alnylam Pharmaceuticals Inc. | 29 | $16,765 |
| Recordati_rare_diseases_inc. | 8 | $11,480 |
| Bioverativ Therapeutics Inc. | 6 | $6,090 |
| Dova Pharmaceuticals | 4 | $5,523 |
| Biocryst Pharmaceuticals, Inc. | 2 | $4,125 |
| Swedish Orphan Biovitrum AB | 1 | $3,000 |
| Biocryst US Sales Co., LLC | 2 | $2,841 |
| Sanofi-aventis U.S. LLC | 2 | $2,542 |
| Amgen | 11 | $2,140 |
| Incyte Corporation | 3 | $2,045 |
| Sobi, Inc | 17 | $397 |
| Apellis Pharmaceuticals, Inc. | 4 | $382 |
| Beone Medicines USA, Inc. | 4 | $87 |
| Bristol Myers Squibb | 4 | $83 |
| Johnson & Johnson | 3 | $72 |
| AbbVie | 2 | $46 |
| Blueprint Medicines Corporation | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $31 |
| Agios Pharmaceuticals, Inc. | 1 | $25 |
| Grifols USA, LLC | 1 | $23 |
| Beigene USA, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$630,689 in reported general payments places this provider in the 95th percentile of 178 hematology providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 14 | $7,975 |
Paid to pharmacies, not to this prescriber.
Other hematology in Los Angeles
- Doris QuonLos Angeles$1.5M
- Caroline PiatekLos Angeles$391K
- Anil TulpuleLos Angeles$79K
- Imran SiddiqiLos Angeles$59K
- Carol KasperLos Angeles$58K
- Everett MeyerStanford$2.1M
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Hope RugoSan Francisco$537K
- Alexey DanilovDuarte$407K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.